Related Experiment Video
Updated: Apr 16, 2026
Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines
Published on: October 8, 2015
Precision therapy for BRAF V600E-mutated ameloblastoma: Systematic review insights
Yuqing Zhou1, Jingrui Yi1, Fatemeh Momen-Heravi2
1State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, Hubei Province, 430079, PR China.
The BRAF V600E mutation is a key driver in ameloblastoma, found in 72.1% of cases. Targeted therapy shows promising results for BRAF V600E-mutated ameloblastoma, potentially reducing surgical needs.
Area of Science:
- Oncology
- Molecular Biology
- Oral Pathology
Background:
- Ameloblastoma is a rare, locally aggressive odontogenic tumor.
- The BRAF V600E mutation is the most common molecular alteration, activating the MAPK pathway.
Purpose of the Study:
- To systematically review and meta-analyze the prevalence of BRAF V600E.
- To evaluate treatment outcomes in BRAF V600E-mutated ameloblastoma cases.
Main Methods:
- Systematic review and meta-analysis of 36 studies.
- Inclusion of 2034 patients for prevalence analysis.
- Analysis of 12 studies with 21 patients for treatment outcomes.
Main Results:
- Pooled BRAF V600E mutation prevalence of 72.1% (95% CI: 67.1-76.6%).
- Higher prevalence in mandibular tumors (77.5%).
- Most patients receiving targeted therapy showed partial or complete radiological response.
Conclusions:
- BRAF V600E is the predominant oncogenic driver in ameloblastoma.
- Targeted therapy targeting BRAF V600E shows promising efficacy.
- Molecular testing and targeted therapy integration may reduce surgical morbidity.
More Related Videos
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...